Regulation of diamine oxidase expression by β2-adrenoceptors in normal and hypertrophic rat kidney

The administration of preferential adrenergic receptor antagonists to uninephrectomized rats revealed the $\text{β}{}_2\text{-}\text{adrenergic}$ mediation in diamine oxidase activity increase that occurs in the remaining kidney undergoing compensatory hypertrophy. In fact, $\text{β}{}_1\text{,β}{}_2\text{-}$ or $\text{β}{}_2\text{-}$, but not $\text{α}{}_1\text{-}$, $\text{α}{}_2\text{-}$, or $\text{β}{}_1\text{-}\text{receptor-blocking}$ this enzyme enhancement. Further studies with adrenoceptor agonists, such as epinephrine ($\text{α}{}_1$, $\text{α}{}_2$, $\text{β}{}_1$, $\text{β}{}_2$), isoproterenol ($\text{β}{}_1$, $\text{β}{}_2$) or terbutaline ($\text{β}{}_2$) showed that also in normal rat kidney diamine oxidase activity is under the control of $\text{catecholamine}\text{-β}{}_2\text{-}\text{receptors}$ through a mechanism that involves new synthesis of mRNA and protein. Theophylline, an inhibitor of phosphodiesterase, or forskolin, an activator of adenyl cyclase, increased diamine oxidase activity as does epinephrine or nephrectomy. Thus, catecholamine-triggered $\text{β}{}_2\text{-}\text{receptors}$ coupled to adenyl cyclase are involved in the regulation of diamine oxidase activity in normal and hypertrophic rat kidney.